Jul 082018

The FDA approved a new indication for the antibiotic combination ceftazidime and avibactam (marketed as Avycaz), for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults.

The drug was approved originally in 2015 for complicated intra-abdominal infections (in combination with metronidazole) and got another indication in 2017 for complicated urinary tract infections and pyelonephritis.

The ceftazidime and avibactam combination is indicated for health care-associated pneumonias presumed due to gram-negative bacteria such as E. coli, Klebsiella, Enterobacter, and Pseudomonas.

Ceftazidime (sold as Fortaz or Tazicef, or as a generic) is a cephalosporin active against gram-negative (including anti-Pseudomonas activity), gram-positive and anaerobic bacteria.

Avibactam is a β-lactamase inhibitor that protects ceftazidime from degradation by β-lactamase enzymes produced by resistant bacteria.

The new indication was granted based on results of a phase 3 randomized trial enrolling 870 adults with hospital-acquired pneumonias, including VAP. Patients received either meropenem or Avycaz for 7 to 14 days. Patients receviing Avycaz had a 9.6% 28-day mortality (the primary endpoint) compared with 8.3% among patients receiving meropenem.

Avycaz has activity against carbapenem-resistant gram-negative rods (Enterobacteriaceae), as do recently approved antibiotic combinations meropenem-vaborbactam (Vabomere) and ceftolozane-tazobactam (Zerbaxa).

Get our weekly email update, and explore our library of practice updates and review articles.

PulmCCM is an independent publication not affiliated with or endorsed by any organization, society or journal referenced on the website. (Terms of Use | Privacy Policy)


Ceftazidime and avibactam (Avycaz) approved for hospital-acquired pneumonias